Patent intelligence · US
US 12208071
Glucagon receptor antagonists
Glucagon receptor antagonists
Patent details — US 12208071
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 28, 2025
- Expiration
- Jan 23, 2045
- Applicant
- Ligand Pharmaceuticals Incorporated
- Claims
- 20
- CPC classes
- A61K, A61K31/155, A61K31/185, A61K31/366
Quick answer
US 12208071 (Glucagon receptor antagonists) is held by Ligand Pharmaceuticals Incorporated. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ligand Pharmaceuticals Incorporated
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/155, A61K31/185, A61K31/366, A61K31/427, A61K31/4439
More from Ligand Pharmaceuticals Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12403087
Topical antiviral compositions, delivery systems, and methods of using the same
granted -
US 12319651
Crystalline forms and methods of producing crystalline forms of a compound
granted -
US 12246014
Azetidine derivatives
granted -
US 12123012
Methods and compositions for nucleic acid and protein payload delivery
granted -
US 11970482
Acetal compounds and therapeutic uses thereof
granted -
US 11952364
TRK inhibitors useful as anticancer drugs
granted -
US 11773110
Heterocycle amines and uses thereof
granted
Frequently asked questions
What is US patent 12208071?
US 12208071 (Glucagon receptor antagonists) is held by Ligand Pharmaceuticals Incorporated. Status: granted. Granted Jan 28, 2025. Expires Jan 23, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12208071?
Ligand Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 133 pharmaceutical patents for this assignee.
When does US 12208071 expire?
Our index shows an expiration date of Jan 23, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.